Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

JANSSEN - CILAG FARMACÊUTICA LDA

NIF 500189412
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €24,814,006 151 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €24,814,006 151 contracts
A2 · Late Publication €42,712,129,159 4,935 contracts
Contract published to BASE more than 10 days after the signing date
LOW €42,712,129,159 4,935 contracts
A5 · Threshold Splitting €22,743,051 177 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €22,743,051 177 contracts
A6 · Low Competition €91,915,793 97 contracts
Only one bidder participated in a competitive procedure
MEDIUM €91,915,793 97 contracts
A9 · Price Overrun €50,998 5 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €12,223 3 contracts
MEDIUM €38,775 2 contracts
A9 · Abnormal Price Reduction €49,772,190,889 1,586 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €49,772,190,889 1,586 contracts
B5 · Benford's Law Deviation €1,119,077,276 4 contracts
Entity's contract values deviate from the Benford leading-digit distribution (chi-square goodness-of-fit, min 20 contracts). Score: 35 (p<0.05) or 55 (p<0.01).
MEDIUM €1,119,077,276 4 contracts
C3 · Missing Mandatory Fields €45,926,897 112 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €45,926,897 112 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

693
€6,293,597,958
51
€4,427,745,954
117
€2,755,649,371
512
€1,547,449,221
127
€1,465,498,131
70
€1,451,746,778
91
€1,404,595,235
225
€1,393,538,222
160
€1,387,505,100
264
€1,384,325,190
77
€1,371,811,757
42
€1,345,899,313
474
€1,321,027,153
359
€1,248,942,630
31
€1,247,538,126
44
€1,222,389,256
47
€1,218,900,423
46
€1,207,957,071
101
€1,152,390,544
216
€1,113,648,059
Page 1 of 4 · 70 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction B5 · Benford's Law Deviation C3 · Missing Mandatory Fields

Page 1 of 4 · 177 contracts

SP 652-2026 Aquisição de Golimumab 50 mg/0.5 ml Sol inj Caneta 0.5 ml SC, para a ULSTMAD, EPE (AQ 2025/1589)
PT · 13655598 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,761 2026-01-28
AD/4144/2025 Aquisição de Amivantamab 50 mg/ml Sol inj Fr 7 ml IV, para a ULSTMAD, EPE
PT · 13701838 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€73,136 2026-01-14
ADCM 4858/25 - Medicamentos Diversos
PT · 13511880 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€74,283 2025-11-14
61/5167/2025 - Medicamento Ustecinumab 45 mg/0.5 ml Sol inj Ser 0.5 ml SC
PT · 12028291 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€72,288 2025-11-11
61/5019/2025 - Medicamento Ustecinumab 90 mg/1 ml Sol inj Ser 1 ml SC
PT · 12961136 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€144,222 2025-11-06
MEDICAMENTOS
PT · 11896031 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€73,010 2025-11-03
Medicamento Ibrutinib 420 mg Comp.
PT · 13351146 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€71,399 2025-10-30
ADCM 4526/25 - MEDICAMENTOS
PT · 11949028 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,625 2025-10-28
ADCM 4491/25 - MEDICAMENTOS
PT · 11907407 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€74,030 2025-10-23
1708425 Teclistamab 2 apresentações Doente autorizado - Medicamento Novo
PT · 11847340 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,844 2025-10-23
ADCM 4491/25 - MEDICAMENTOS
PT · 3710247d4fa930f5a6ca · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€73,937 2025-10-23
251Y000291 - AQUISIÇÃO DE MEDICAMENTOS DIVERSOS - 1428/2025
PT · 11822637 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€19,557 2025-10-22
Q1/2318/2025 - AGREGAÇÃO URGENTE - MEDICAMENTOS DO FORO ONCOLÓGICO E IMUNOMODULADORES
PT · 11976821 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,294,078 2025-10-22
Aquisição de Medicamento Exclusivo Escetamina [28 mg; Sol Pulv Nas; Frs]
PT · 11824967 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€72,308 2025-10-16
PALIPERIDONA 50 MG SUSP INJ LP SER IM
PT · 11944470 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,982 2025-10-09
ADCM 3967/25 - MEDICAMENTOS DIVERSOS
PT · 11760019 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€71,919 2025-09-12
ESCETAMINA 28 MG SOLUÇÃO PARA PULVERIZAÇÃO NASAL
PT · 11672681 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,523 2025-08-29
ESCETAMINA 28 MG SOLUÇÃO PARA PULVERIZAÇÃO NASAL
PT · 11673036 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,523 2025-08-29
Aquisição de USTECINUMAB 90MG/1ML INJ SER SC. E USTECINUMAB [130 MG; SOL INJ; FRS].
PT · 12939379 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€149,969 2025-08-25
AQUISIÇÃO URGENTE DE DARATUMUMAB 120MG, TALQUETAMAB 40MG
PT · 11944406 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€142,632 2025-08-07
Medicamentos
PT · 87d4c78f8b0aa36e9bc2 · Ajuste Direto Regime G...
A2 · Late Publication A5 · Threshold Splitting
€4,819 2025-08-04
NP AUE - JANSSEN- ERDAFITINIB
PT · 11646056 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€145,797 2025-07-30
06/02676.11/2025 - Aquisição de "Paliperidona 50 mg Susp inj LP Ser IM" ao abrigo do Acordo Quadro nº 2022/173
PT · 11520300 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€19,931 2025-06-13
Aquisição Medicamento talquetamab inj. 2mg/ml 1.5ml sc e talquetamab inj. 40mg/1ml sc
PT · 11738150 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€147,705 2025-05-28
Aquisição Medicamentos Exclusivos Janssen Cilag – Paliperidona LP - Ano 2025
PT · 11455724 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,119 2025-05-21
1315725 Medicamentos Exclusivos Amivantamab 50 mg/ml Sol inj Fr 7 ml IV Ano 2025
PT · 11367073 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€73,136 2025-04-22
USTECINUMAB 130 MG/26 ML SOL INJ FR 26 ML IV - STELARA
PT · 11458125 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€72,491 2025-04-16
AMIVANTAMAB
PT · 11460018 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€147,734 2025-04-14
MEDICAMENTOS USADOS TRATAMENTO HIPERTENSAO PULMONAR
PT · 11336629 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€146,172 2025-04-09
Aquisição de INFLiximab 100 mg Pó conc sol inj Fr IV (REMICADE/ JANSSEN)
PT · 11461017 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€73,708 2025-04-03
251000303 - VÁRIOS MEDICAMENTOS
PT · 11296611 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€72,621 2025-03-20
MEDICAMENTOS
PT · 11701210 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,840 2025-02-28
51/36/2025 CPA 2022/55 - Medicamentos diversos
PT · 11325318 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€73,136 2025-02-27
MEDICAMENTOS
PT · 11313206 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€19,131 2025-02-21
Aquisição Medicamentos Exclusivos Janssen-Cilag
PT · 12026983 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€144,310 2025-02-18
VÁRIOS MEDICAMENTOS
PT · 11191927 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€71,862 2025-01-20
Medicamentos
PT · 11324981 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€74,849 2025-01-08
BEAD20240621 - AQUISIÇÃO DE ANTIPSICOTICOS - PALIPERIDONA
PT · 11088780 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A6 · Low Competition
€73,711 2024-12-16
Aquisição de INFLIXIMAB [120 MG/ML; SOL INJ; CANETA], UPADACITINIB [15 MG; CÁP LP/ COMP LP], GUSELCUMAB [100 MG/1 ML; SOL INJ; CANETA] e OFATUMUMAB [20 MG/0.4 ML; SOL INJ; CANETA] ao abrigo do acordo quadro 2023/491
PT · 11811671 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€74,214 2024-12-12
VÁRIOS MEDICAMENTOS
PT · 11075256 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,493 2024-11-28
Aquisição de APALUTAMIDA [60 MG; CÁP/ COMP], CARFILZOMIB [10 MG; PÓ SOL INJ; FRS] e CARFILZOMIB [30 MG; PÓ SOL INJ; FRS] ao abrigo do acordo quadro 2023/491
PT · 11064141 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€145,420 2024-11-28
1141/2024 - Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2023/491 (Medicamentos do foro oncológico e imunomoduladores), 2023/671 (Medicamentos diversos), 2023/304 (Medicamentos do grupo 4: sangue), 2022/173 (Medicamentos diversos), 2023/492 (Medicamentos anti-infeciosos)
PT · 11290135 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€19,076 2024-11-25
Aquisição de RUXOLITINIB [5 MG; CÁP/ COMP] e IBRUTINIB [560 MG; CÁP/COMP] ao abrigo do Acordo Quadro 2023/491
PT · 11024602 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€73,350 2024-11-07
Aquisição de Medicamentos/ produtos farmacêuticos diversos 3
PT · 10727188 · Consulta Prévia
A5 · Threshold Splitting A2 · Late Publication +1
€74,979 2024-04-03
MEDICAMENTOS
PT · 8f69ac2bc3b58caa612b · Ajuste Direto Regime G...
A5 · Threshold Splitting
€4,947 2024-03-26
VÁRIOS MEDICAMENTOS
PT · 10672000 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€74,708 2024-03-12
APALUTAMIDA 60 MG COMP (PC.00758.2024)
PT · 10628550 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€19,573 2024-02-28
MEDICAMENTOS
PT · 10623498 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication +1
€71,652 2024-02-20
PA 37/PA/HPSD/2024 - Aquisição de bens para os Serviços Farmacêuticos do hospital Prisional.
PT · 10554340 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,098 2024-02-05
NP EXCL JANSSEN -
PT · 10940898 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€146,272 2024-01-19
Next →
Overview
Total Value Won
€50,579,567,987
Contracts Won
7,070
Score 231630 · CRITICAL RISK
NIF
500189412
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

No director data imported yet.

Director and fiscal identity data for Portuguese companies can be found in the Registo Comercial (publicacoes.mj.pt).

Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned